Quantcast

Latest Interferon Stories

2014-04-14 12:05:11

High cure rates achieved with fixed-dose interferon-free and ribavirin-free regimen Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver...

2014-04-14 11:03:19

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of...

Hepatitis C Treatment Without The Side Effects Of Interferon
2014-04-14 10:21:29

redOrbit Staff & Wire Reports - Your Universe Online A new orally-administered antiviral therapy has reportedly cured hepatitis C infection in over 90 percent of patients with liver cirrhosis, according to research published Saturday in the New England Journal of Medicine. Previously, the only treatment method that showed effectiveness against hepatitis C was interferon. However, patients treated with this agent often suffered relapses and experienced multiple adverse side effects....

2014-04-12 12:20:06

LONDON, April 12, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93 percent of patients with the hepatitis C virus (HCV) and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated with simeprevir administered once daily with Gilead Sciences, Inc.'s sofosbuvir for 12 weeks achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The addition of...

2014-04-03 12:29:57

Preclinical Study Published in Cell Reports Identifies Key Signaling Pathways in Innate Immune Sensing of Malaria Parasite During Liver Stage Infection SEATTLE, April 3, 2014 /PRNewswire/ -- Seattle BioMed today announced researchers have identified the presence of an innate immune response to the malaria parasite during liver stage infection. Results of the study were published online today in Cell Reports. Key points: -- Following transmission of the malaria parasite by mosquito bite,...

2014-04-02 08:33:17

MOSCOW, April 2, 2014 /PRNewswire/ -- Hepatera Ltd. [http://www.hepatera.ru/?ln=en ] announces initiation of a clinical trial investigating Myrcludex B in chronically HBV infected patients who are also infected with hepatitis delta virus (HDV). Hepatera is financed by Maxwell Biotech Venture Fund [http://www.maxwellbiotech.com ] formed with the participation of RVC [http://www.rusventure.ru/en ] - Russia's government fund of venture capital funds. Hepatera was...

2014-04-02 08:32:34

OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin CORK, Ireland, April 2, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and...

2014-03-28 09:26:17

A combination of genetic predisposition and environmental factors is believed to cause autoimmune (type 1) diabetes. A study published on March 27th in PLOS Pathogens gets at the mechanisms by which rotavirus infection contributes to autoimmune diabetes in a mouse model of the disease. NOD (for non-obese diabetic) mice are prone to develop diabetes, and infection with rotavirus accelerates onset of the disease. Barbara Coulson and colleagues, from The University of Melbourne, Australia,...

2014-03-28 08:27:04

ASHEVILLE, N.C., March 28, 2014 /PRNewswire/ -- It's hard to imagine heavyweight hematologists publicly squaring off in support of an off-label blood cancer drug. And yet, today, that's exactly what happened in an "Open Letter to the MPN Community of the United States," (http://mpnforum.com/an-open-letter/) published in the April issue of MPNforum Magazine. (www.mpnforum.com) Photo - http://photos.prnewswire.com/prnh/20140328/PH92830-a Photo -...

2014-03-26 23:28:09

Markets Research Reports.biz added deep and professional market research reports on "Global Cloud Computing: Infrastructure, Platforms, and Services 2014 - 2019" Market Analysis and Overview Albany, NY (PRWEB) March 26, 2014 Cloud is an enabler of business process change as it facilitates enterprise to realize key benefits including expenditure reduction (CapEx and OpEx), service development and delivery efficiencies, and greater flexibility to meet evolving business needs....


Latest Interferon Reference Libraries

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (1 articles) »
Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related